Auxilium Pharmaceuticals has dosed its first patient in an open-label Phase IIIb trial of Xiaflex, used for treating adult Dupuytren’s contracture patients with multiple palpable cords.

The Phase IIIb study is expected to enroll approximately 60 patients who will be monitored for 60 days following their last injection.

The study is designed to assess the safety and efficacy of concurrent administration of two injections of Xiaflex into the same hand of subjects with at least two of Dupuytren’s contractures caused by palpable cords.

Safety assessments include immunogenicity testing, while efficacy assessments include measuring finger goniometry and range of motion of the treated joints on days 1, 8, 30, and 60, following the first cycle of two injections.

The findings from the study are anticipated in the second half of 2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.